Serratia marcescens endocarditis treated with ceftazidime. A case report.
A 14-year-old Black girl developed Serratia marcescens endocarditis following a mitral valve repair. This was refractory to treatment with several courses of antibiotics and valve replacement, and was eventually cured after a second valve replacement and treatment with ceftazidime (GR 20263 Glaxo), a new cephalosporin derivative.
D000293:Adolescent; D002442:Ceftazidime; D002511:Cephalosporins / Q000627:therapeutic use*; D004697:Endocarditis, Bacterial / Q000188:drug therapy*; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D005260:Female; D006350:Heart Valve Prosthesis; D006801:Humans; D008943:Mitral Valve / Q000601:surgery; D012706:Serratia marcescens / Q000302:isolation & purification
D002511:Cephalosporins; D002442:Ceftazidime